In a note published today, Piper Jaffray reiterated a Neutral rating on biotech firm Sequenom SQNM with a $6.25 price target. That implies significant upside from where Sequenom currently trades.
“Sequenom's management team described a stable inflow of samples following the mid-October launch of its MaterniT21 assay (Down syndrome). As a reminder, Sequenom is relying on ~40 blood draw stations across the country to draw and process (centrifuged, frozen) samples for testing. By mid-2012, Sequenom plans to have a process in place where freezing will not be required, enabling blood draws to be taken at a physician office and shipped directly to Sequenom's reference lab, which should benefit MaterniT21 test volumes, in our opinion,” Piper Jaffray said in the note.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Analyst ColorNewsPrice TargetReiterationIntraday UpdateMarketsAnalyst RatingsTrading Ideas
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in